Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AVI BioPharma and Eleos sign cross-license agreement
Under the terms of the agreement, AVI is granting Eleos an exclusive license to AVI's Neugene third-generation antisense chemistry to treat cancer with p53-related drugs. In return, Eleos
Under the terms of the agreement, AVI is granting Eleos an exclusive license to AVI's Neugene third-generation antisense chemistry to treat cancer with p53-related drugs. In return, Eleos
Squamous cell carcinoma SCC of the head and neck continues to be a clinical challenge. Even with the use of modern therapeutic options, 50% of all patients will
RNA interference, or RNAi, is an emerging field of biotechnology that involves blocking production of disease causing proteins. The studies will utilize Mirus Bio’s nucleic acid delivery platforms
As part of this collaboration, Organon has acquired an equity interest in HUYA, which identifies, licenses and develops Chinese drug candidates. Under the collaboration agreement, HUYA will support
Although the US biotech company will not release end of year results until February, the update reflected a rise in its sales forecast for 2006 and 2007. Pharmion
Tests evaluating Viprovex as a potential influenza infection treatment were conducted at Virion Systems, a Maryland biotechnology corporation. The company believes that preliminary results of Viprovex treatment of
Aptamers are chemically synthesized single-stranded nucleic acids, which can be made to imitate antibodies. As part of the collaboration, Archemix will use its proprietary SELEX technology to discover
Enrollment of the first patient is expected this month. Werner Tschollar, chief medical officer of Xytis, said: “We are working with the London School of Hygiene and Tropical
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting. If approved for marketing, the drug
The first study involved 75 patients in a variety of chronic conditions associated with neuropathic pain and demonstrated a statistically significant improvement in pain compared to placebo as